VERAXA Biotech (NASDAQ: VRXA) has announced a significant regulatory milestone, receiving Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI) that supports the development strategy for its lead BiTAC®-TCE program. The feedback provides early guidance on the biological rationale, safety assessments, and non-clinical development plan for the company's novel therapeutic platform, as detailed in the press release (https://ibn.fm/zBiDU). This regulatory input is expected to reduce development uncertainty by offering greater clarity before the company advances toward clinical studies.
The BiTAC®-TCE platform is designed to create bispecific T-cell engagers that harness the immune system to target cancer cells. VERAXA's lead candidate previously demonstrated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company is building a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats.
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping to align development strategies with regulatory expectations regarding safety, tolerability, and efficacy. The PEI's positive feedback marks an important step as VERAXA continues to progress its manufacturing and development efforts for next-generation antibody therapeutics.
Investors can find the latest news and updates regarding VRXA in the company's newsroom at https://ibn.fm/VRXA. The company remains focused on advancing its BiTAC®-TCE program and other pipeline assets to address unmet needs in oncology.
Forward-looking statements in this article involve risks and uncertainties, including those described in the company's SEC filings. VERAXA undertakes no duty to update this information unless required by law.
